Lipocine (NASDAQ: LPCN) files updated corporate investor presentation

Filing Impact

(High)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

Lipocine Inc. filed a current report to make available an updated corporate presentation used in meetings with investors, analysts and other stakeholders. The updated presentation is included as Exhibit 99.1 to the report. Lipocine’s common stock, par value $0.0001 per share, trades on The NASDAQ Stock Market LLC under the symbol LPCN.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

02/18/2026 - 09:37 AM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):

February 18, 2026

LIPOCINE INC.

(Exact name of registrant as specified in its charter)

Commission File No. 001-36357

Delaware

99-0370688

(State or other jurisdiction

of incorporation)

(IRS Employer

Identification Number)

675 Arapeen Drive, Suite 202

Salt Lake City, Utah 84108

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (801) 994-7383

Former name or former address, if changed since last report: Not Applicable

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		LPCN		The NASDAQ Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR § 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR § 240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01

Other Events

The Company has updated its corporate presentation that it uses when meeting with investors, analysts and others. The presentation is filed as Exhibit 99.1.

Item 9.01

Financial Statements and Exhibits.

(d)

Exhibits

The following exhibits are filed with this report:

Exhibit No.		Description

99.1		Corporate Presentation

104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		LIPOCINE INC.

Date:	February 18, 2026	By:	/s/ Mahesh V. Patel
			Mahesh V. Patel
			President and Chief Executive Officer

Exhibit 99.1

Source: View Original Filing on SEC EDGAR

FAQ

What did Lipocine Inc. (LPCN) report in its latest 8-K filing?

Lipocine Inc. filed a current report to furnish an updated corporate presentation. This presentation is used in meetings with investors, analysts and others and is attached as Exhibit 99.1 to the filing for public access.

What is Exhibit 99.1 in Lipocine Inc. (LPCN)’s February 18, 2026 filing?

Exhibit 99.1 is Lipocine Inc.’s updated corporate presentation. The company uses this presentation when meeting with investors, analysts and other interested parties, and it has been formally filed so the market can review the same information.

On which exchange is Lipocine Inc. (LPCN) common stock listed?

Lipocine Inc.’s common stock, with a par value of $0.0001 per share, is listed on The NASDAQ Stock Market LLC. The trading symbol for the company’s shares on this exchange is LPCN, as stated in the filing.

Who signed Lipocine Inc. (LPCN)’s February 18, 2026 report?

The report was signed on behalf of Lipocine Inc. by Mahesh V. Patel. He is identified in the document as the company’s President and Chief Executive Officer and executed the filing under the Securities Exchange Act of 1934.

What additional exhibit is referenced besides the Lipocine (LPCN) presentation?

The filing also references Exhibit 104, described as the Cover Page Interactive Data File. This file is embedded within the Inline XBRL document, providing structured data for the cover page information of the current report.

Filing Exhibits & Attachments

48 documents

Lipocine (NASDAQ: LPCN) files updated corporate investor presentation

Rhea-AI Filing Summary

Positive

Negative